A Lewis base catalyst Trip-SMe (Trip = triptycenyl) for electrophilic aromatic halogenationusing N-halosuccinimides (NXS) is introduced. In the presence of an appropriate activator (as a non-coordinating-anion source), a series of unactivated aromatic compounds were halogenated at ambient temperature using NXS. This catalytic system was applicable to transformations that are currently unachievable
Neighboring Group Participation in Solvolysis. X. Dissection of Ar<sub>1</sub>-5 and Ar<sub>2</sub>-6 Pathways in Trifluoroacetolysis of 4-Arylbutyl 6-Methyl-2-naphthalenesulfonates
Trifluoroacetolysis rates and products were determined for eleven 4-(m- and p-substituted phenyl) butyl 6-methyl-2-naphthalenesulfonates. Most substrates solvolyze predominantly or even exclusively with aryl assisted (kΔ) pathway. Dissection of kΔ into Ar1-5 and Ar2-6 components was performed by means of quantitative 13C NMR study of suitably labeled p-methyl and p-fluoro derivatives; the results were
Nucleophilic Addition to a <i>p</i>-Benzyne Derived from an Enediyne: A New Mechanism for Halide Incorporation into Biomolecules
作者:Charles L. Perrin、Betsy L. Rodgers、Joseph M. O'Connor
DOI:10.1021/ja070023e
日期:2007.4.1
Biosynthesis of haloaromatics ordinarily occurs by electrophilic attack of an activated halogen species on an electron-rich aromatic ring. We now present the discovery of a new reaction whereby a nucleophilic halide anion can be attached even to an aromatic ring without activating substituents. We show that the enediyne cyclodeca-1,5-diyn-3-ene, in the presence of lithium halide and a weak acid, is
CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
申请人:Carter Percy H.
公开号:US20090124668A1
公开(公告)日:2009-05-14
The present application describes modulators of MCP-1 of formula (I):
or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.
N-ALKYLATED DIAMINOPROPANE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
申请人:Carter Percy H.
公开号:US20080113976A1
公开(公告)日:2008-05-15
The present application describes modulators of MCP-1 of formula (I):
or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.